Market Closed -
Nyse
04:00:00 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
0.68
USD
|
-6.54%
|
|
-8.98%
|
-5.16%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
194.8
|
187.5
|
168.1
|
139.8
|
56.42
|
60.26
|
-
|
-
|
Enterprise Value (EV)
1 |
181.4
|
187.5
|
168.1
|
139.8
|
56.42
|
49.06
|
74.16
|
73.96
|
P/E ratio
|
-11.6
x
|
-8.64
x
|
-6.16
x
|
-4.42
x
|
-1.43
x
|
-1.51
x
|
-2.13
x
|
-4.86
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
11,391
x
|
13,960
x
|
1,867
x
|
456
x
|
72.8
x
|
17
x
|
3.96
x
|
1.26
x
|
EV / Revenue
|
10,606
x
|
13,960
x
|
1,867
x
|
456
x
|
72.8
x
|
13.8
x
|
4.87
x
|
1.55
x
|
EV / EBITDA
|
-11.5
x
|
-9.13
x
|
-
|
-5.04
x
|
-1.73
x
|
-1.55
x
|
-2.86
x
|
-14.2
x
|
EV / FCF
|
-
|
-10.2
x
|
-7.7
x
|
-
|
-
|
-1.81
x
|
-2.96
x
|
247
x
|
FCF Yield
|
-
|
-9.82%
|
-13%
|
-
|
-
|
-55.2%
|
-33.8%
|
0.41%
|
Price to Book
|
13.7
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
41,092
|
48,198
|
53,536
|
57,521
|
78,686
|
82,824
|
-
|
-
|
Reference price
2 |
4.740
|
3.890
|
3.140
|
2.430
|
0.7170
|
0.6800
|
0.6800
|
0.6800
|
Announcement Date
|
2/20/20
|
3/22/21
|
3/30/22
|
3/15/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.0171
|
0.0134
|
0.09
|
0.3064
|
0.7753
|
3.55
|
15.21
|
47.64
|
EBITDA
1 |
-15.83
|
-20.53
|
-
|
-27.73
|
-32.55
|
-31.7
|
-25.9
|
-5.2
|
EBIT
1 |
-16.04
|
-21.25
|
-28.33
|
-31.78
|
-35.99
|
-34.95
|
-29.77
|
-11.3
|
Operating Margin
|
-93,818.25%
|
-158,211.62%
|
-31,467.21%
|
-10,372.42%
|
-4,641.78%
|
-984.51%
|
-195.66%
|
-23.72%
|
Earnings before Tax (EBT)
1 |
-16.1
|
-20.4
|
-26.99
|
-30.6
|
-35.68
|
-35.57
|
-30
|
-11.55
|
Net income
1 |
-16.1
|
-20.35
|
-26.81
|
-30.27
|
-35.32
|
-35.48
|
-31
|
-12.6
|
Net margin
|
-94,146.55%
|
-151,542.22%
|
-29,780.84%
|
-9,879.17%
|
-4,555.54%
|
-999.39%
|
-203.77%
|
-26.45%
|
EPS
2 |
-0.4100
|
-0.4500
|
-0.5100
|
-0.5500
|
-0.5000
|
-0.4500
|
-0.3200
|
-0.1400
|
Free Cash Flow
1 |
-
|
-18.41
|
-21.83
|
-
|
-
|
-27.1
|
-25.05
|
0.3
|
FCF margin
|
-
|
-137,046.17%
|
-24,241.98%
|
-
|
-
|
-763.38%
|
-164.66%
|
0.63%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/20/20
|
3/22/21
|
3/30/22
|
3/15/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.0142
|
0.1142
|
0.0398
|
0.0327
|
0.1197
|
0.1498
|
0.2163
|
0.1652
|
0.244
|
0.1715
|
0.42
|
0.86
|
1.84
|
1.3
|
1.8
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-8.079
|
-
|
-7.819
|
-7.978
|
-7.71
|
-8.2
|
-8.2
|
-7.7
|
-
|
-
|
EBIT
1 |
-8.785
|
-7.677
|
-8.099
|
-7.993
|
-8.011
|
-9.045
|
-9.549
|
-8.653
|
-8.741
|
-8.384
|
-8.808
|
-8.794
|
-8.641
|
-7.9
|
-7.4
|
Operating Margin
|
-61,692.56%
|
-6,721.81%
|
-20,376.05%
|
-24,435.83%
|
-6,691.16%
|
-6,037.67%
|
-4,414.52%
|
-5,237.61%
|
-3,582.64%
|
-4,887.78%
|
-2,097.02%
|
-1,022.53%
|
-469.61%
|
-607.69%
|
-411.11%
|
Earnings before Tax (EBT)
1 |
-8.21
|
-7.718
|
-7.732
|
-7.812
|
-7.336
|
-8.873
|
-9.551
|
-8.453
|
-8.8
|
-8.472
|
-8.9
|
-9
|
-9
|
-7.9
|
-7.4
|
Net income
1 |
-7.933
|
-7.634
|
-7.65
|
-7.743
|
-7.242
|
-8.78
|
-9.471
|
-8.37
|
-8.698
|
-8.367
|
-9.7
|
-10.1
|
-9.7
|
-7.9
|
-7.4
|
Net margin
|
-55,710.04%
|
-6,684.2%
|
-19,244.53%
|
-23,671.57%
|
-6,049.2%
|
-5,860.46%
|
-4,378.43%
|
-5,066.46%
|
-3,565.29%
|
-4,877.81%
|
-2,309.52%
|
-1,174.42%
|
-527.17%
|
-607.69%
|
-411.11%
|
EPS
2 |
-0.1500
|
-0.1400
|
-0.1400
|
-0.1400
|
-0.1300
|
-0.1500
|
-0.1400
|
-0.1100
|
-0.1100
|
-0.1000
|
-0.1200
|
-0.1200
|
-0.1200
|
-0.0700
|
-0.0700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
5/11/22
|
8/10/22
|
11/14/22
|
3/15/23
|
5/10/23
|
8/14/23
|
11/14/23
|
3/25/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
13.9
|
13.7
|
Net Cash position
1 |
13.4
|
-
|
-
|
-
|
-
|
11.2
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.5367
x
|
-2.635
x
|
Free Cash Flow
1 |
-
|
-18.4
|
-21.8
|
-
|
-
|
-27.1
|
-25.1
|
0.3
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
0.3500
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.51
|
1.94
|
0.97
|
-
|
-
|
1.4
|
1.73
|
3.3
|
Capex / Sales
|
2,989.88%
|
14,453.16%
|
1,081.25%
|
-
|
-
|
39.44%
|
11.39%
|
6.93%
|
Announcement Date
|
2/20/20
|
3/22/21
|
3/30/22
|
3/15/23
|
3/25/24
|
-
|
-
|
-
|
Last Close Price
0.68
USD Average target price
3.633
USD Spread / Average Target +434.31% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.16% | 60.26M | | -36.44% | 9.2B | | -3.29% | 3.12B | | +19.31% | 2.8B | | -18.71% | 2.07B | | -22.03% | 1.59B | | +64.58% | 1.44B | | +34.58% | 830M | | -7.42% | 724M | | -25.51% | 507M |
Bio Diagnostics & Testing
|